Therapeutic Small Molecule Regulators of RNA Transcripts

A global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify innovation in small molecule regulators of RNA transcripts that are highly selective towards their targets. There is a particular focus on immunologically based diseases, including, but not limited to: rheumatoid arthritis, inflammatory bowel disease and lupus.

Our client is seeking to identify research at an early stage of development focusing on small molecule drugs against RNA, RNA:protein, and RNA:RNA complexes that can specifically up- or down-regulate the expression pattern of a target of interest.

Specific Points of Interest

- Novel methods of targeting RNA to lead to a selective change (increase or decrease) in the expression of a protein of interest
- RNA specific pathways of interest include, but are not limited to: transcription, splicing pathway, translation, mRNA stability, nonsense-mediated decay
- Specific modulation of RNA transcripts for inflammatory pathways and the DNA sensing pathway are of high interest
- Modulation of specific IncRNAs or miRNAs associated with the above pathways is within scope

Out of Scope

- Oligotherapeutics e.g. siRNAs, antisense oligonucleotides
- Gene therapy approaches
- Viral delivery

Stage of Development

Opportunities from basic research to preclinical development are within scope, with research with validation in ex vivo and/or in vivo models being of highest interest.

Submission Information

Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Potential Collaborations for Academics

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include project/PhD funding and research collaborations.